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Objectives: In Denmark, patients with rheumatoid arthritis (RA) are registered in the nation-
wide clinical DANBIO quality register and the Danish National Patient Registry (DNPR). The 
aim was to study the validity of the RA diagnosis and to estimate the completeness of relevant 
RA cases in each registry.
Study design and setting: Patients registered for the first time in 2011 with a diagnosis of 
RA were identified in DANBIO and DNPR in January 2013. For DNPR, filters were applied 
to reduce false-positive cases. The diagnosis was verified by a review of patient records. We 
calculated the positive predictive values (PPVs) of the RA diagnosis registrations in DANBIO 
and DNPR, and estimated the registry completeness of relevant RA cases for both DANBIO 
and DNPR. Updated data from 2011 to 2015 from DANBIO were retrieved to identify patients 
with delayed registration, and the registry completeness and PPV was recalculated.
Results: We identified 1,678 unique patients in DANBIO or in DNPR. The PPV (2013 dataset) 
was 92% in DANBIO and 79% in DNPR. PPV
 
for DANBIO
 
on the 2015 update was 96%. The 
registry completeness of relevant RA cases was 43% in DANBIO, increasing to 91% in the 
2015 update and 90% in DNPR.
Conclusion: DANBIO held a high proportion of true RA cases (96%) and was found to be 
superior to the DNPR (79%) with regard to the validity of the diagnosis. Both registries were 
estimated to have a high completeness of RA cases treated in hospital care (~90%).
Keywords: rheumatoid arthritis, validity, incidence, clinical registry, Denmark
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease, typically involving the 
small joints of hands and feet. The disease requires lifelong monitoring and treatment. 
In the majority of patients, RA limits daily functioning, quality of life, and the ability 
to maintain work, and it imposes high welfare costs as a consequence.1,2 The prevalence 
of RA in Denmark has been estimated to be 0.5%–0.9%.3
In clinical epidemiological research, the validity of the diagnosis is essential to 
draw valid conclusions from studies using registry data. In Denmark, two nation-
wide data sources are available with regard to RA patients: the nationwide DANBIO 
clinical register for inflammatory arthritides, including rheumatoid arthritis (RA), is 
a dedicated clinical quality and research registry used in routine care by all depart-
ments of rheumatology in Denmark.4 The Danish National Patient Registry (DNPR) 
is a nationwide, administrative registry that covers all hospitalizations and outpatient 
visits.5 In DANBIO, detailed longitudinal clinical information about representative 
disease course, patient-reported outcomes (PRO), joint examinations, and medical 
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treatment are collected as part of routine care, whereas DNPR 
data are collected for administrative purposes.
In an earlier study, the validity of RA diagnoses in DNPR 
during the period 1977–2001 was investigated by comparing 
DNPR data with the diagnoses registered in patient records. 
The results showed that the proportion of valid RA diagnoses 
in DNPR varied between 20% and 90%. Correct diagnoses 
were more often found in patients with frequent contacts 
and in patients seen at departments of rheumatology.6 The 
DANBIO registry was established in October 2000 and, 
therefore, had no data available for comparison.4 The annual 
DANBIO report estimates the completeness of patients with 
the RA diagnoses in DANBIO compared to DNPR at ~85% 
for the recent years7; however, no concurrent validation of the 
diagnoses in both registries has previously been undertaken.
Accurate knowledge about the overlap and validity of 
RA diagnoses is important for future research based on 
these two registries. The objective of this study was to study 
the validity of the RA diagnosis (positive predictive value 
[PPV]) and to estimate the completeness of relevant RA 
cases in each registry.
Materials and methods
The DanBiO registry and DnPr
The DANBIO registry (full name: DANBIO – The Danish 
Rheumatologic Database) contains clinical and treatment 
data, which are entered by rheumatologists as part of routine 
care during the disease course of patients with inflammatory 
rheumatic diseases. Patient-reported outcomes (PROs) – 
entered by patients from touchscreens in the waiting area in 
the outpatient clinics – are also collected. DANBIO data are 
used for the monitoring of treatment quality and for research 
purposes.8–12 Initially, DANBIO was a voluntary registry only 
including patients treated with biological drugs; but, since 
2006, it has been mandatory to also include newly referred 
RA patients regardless of treatment and disease duration.4 
By spring 2015, more than 26,000 patients registered with 
RA had been included in DANBIO.7
In Denmark, hospital-based healthcare is funded through 
public taxation. Since 1977, all hospitals are required to 
report administrative data, including diagnostic information, 
for inpatients to the DNPR and, from 1995, also for outpa-
tients.5 During the study period, all diagnoses were coded 
using the ICD-10 classification system.13
Application of unique personal identifiers (assigned to 
all Danish citizens at birth or when achieving citizenship) 
enables accurate linkage of individuals between registries.
study population
In January 2013, data were obtained from both the DANBIO 
and the DNPR, for all patients registered with an RA diagno-
sis during the period between 2001 and 2011. We included 
the following ICD-10 diagnostic codes: M05.9 (seropositive 
RA), M06.0 (seronegative RA), M06.8 (other types of RA), 
and M06.9 (unspecified RA).
Based on the data extracted from the two registries, we 
identified incident RA patients with their first RA diagnosis 
in 2011 (by excluding all patients with a registered RA diag-
nosis during 2001–2010). A total of 2,298 unique patients 
were identified. From this population, we grouped patients 
into three categories: overlapping if they were registered 
in DANBIO and DNPR, DANBIO only if registered in 
DANBIO only, and DNPR only if registered in DNPR only 
(Figure 1).
In order to increase the chances of obtaining true RA 
patients, the DNPR population was limited to patients who 
had a visit with a RA diagnosis at a hospital department of 
rheumatology in 2011, and who had at least one additional 
visit with a RA diagnosis within 90 days after the first visit. 
This was based on the methods used in the former validation 
study, which showed that the chances of retrieving true RA 
cases was much higher when requiring two RA registrations in 
DNPR rather than only one, and with only a minor additional 
gain in restricting to three registrations.6 The filter reduced 
our population to 1,678 unique patients in total (Figure 1).
review of patient records
For the identified population of patients with registered RA 
diagnoses, one rheumatologist at each hospital department 
retrieved the medical records. Based on the information avail-
able in the patient records around the time of diagnosis, the 
rheumatologists categorized patients as having RA based on 
the rheumatologists’ expert opinion. Before data collection, 
two rheumatologic specialists at Gentofte University Hos-
pital evaluated the ACR-87 criteria14 and the expert opinion 
method for categorizing patients as having RA for 80 patients 
and found a perfect match.
For patients who could not be confirmed as having RA, 
a relevant other diagnosis or a possible explanation for lack 
of registration in either DANBIO or DNPR was recorded. 
Rheumatologists were blinded for the registry details of 
the patients. In total, 1,532 patient records (Figure 1) at 21 
hospital departments were reviewed. Of the remaining 146 
patient records, 57 could not be located at the responsible 
hospital, and the remaining 89 patients were treated at 
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Figure 1 results from data retrieval and merged data between the nationwide Clinical register for Patients with rheumatoid arthritis (DanBiO) and the Danish national 
Patient Registry (DNPR), as well as from medical file review; n (%), positive predictive values (PPV), and registry completeness of relevant RA cases.
DANBIO DNPR
DANBIO only DNPR only
Overlapping
(both in DANBIO and
DNPR)
14,185
Unique patients with a
RA diagnosis registered
between 2001 and 2011
Incident patients in 2011
Merge of data from
DANBIO and DNPR
DNPR limited to
registrations from
departments of
rheumatology
DNPR limited to a total
of ≥2 registrations
within 90 days
Review of patient
records
Results from
review of
patient
records
Have RA
125 (78%)
Not RA
27 (17%)
Unknown
9 (5%)
Have RA
400 (97%)
Not RA
11 (3%)
Unknown
1 (0%)
581
Have RA
125 (78%)
Have RA
400+581=
981 (99%)
Not RA
27 (17%)
Unknown
9 (5%)
Not RA
11 (1%)
Unknown
1 (0%)
Have RA
689 (72%)
Not RA
262 (27%)
Unknown
8 (1%)
Results after
DANBIO
data update
PPV of the RA diagnosis in DANBIO
(125+981)/(161+412+581) = 96%
PPV of the RA diagnosis in DANBIO:
(125+400)/(161+412) = 92%
PPV of the RA diagnosis in DNPR:
(689+400)/(959+412) = 79%
Completeness of relevant cases in DNPR:
(689+400)/(125+400+689) = 90%Completeness of relevant cases in DANBIO:(125+400)/(125+400+689) = 43%
Completeness of relevant cases in DANBIO
(125+981)/(125+400+689) = 91%
30,713
2,088664
210 (9%)
210 (11%)
210 (13%)
161 (11%)
77% reviewed
412 (27%)
97% reviewed
959 (63%)
92% reviewed
No record
review
49
No record
review
11
No record
review
86
445 (22%)
423 (25%)
1,345 (67%)
1,045 (62%)
454 (20%) 1,634 (71%) Total number of patients:
2,298
Total number of patients:
2,000
Total number of patients:
1,678
Total number of patients:
1,532
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three hospitals that did not participate in the study (data 
not shown).
Update of data
In 689 RA patients registered in 2011, the review of patient 
records confirmed a valid RA diagnosis in DNPR, but the 
patients were not in the initial DANBIO dataset (Figure 1). 
As the focus on registration into DANBIO has increased over 
time, we retrieved updated data from DANBIO primo 2015 
to investigate whether these patients had been registered in 
DANBIO after the initial data extraction.
analysis
Based on the review of the patient records, the PPV of the RA 
diagnoses in DANBIO and DNPR, respectively, were calcu-
lated as the number of patients with a verified RA diagnosis 
in each registry divided by all patients with records reviewed 
from DANBIO and DNPR, respectively. The completeness 
of relevant RA cases was calculated for each registry as the 
number of verified RA patients in DANBIO and DNPR, 
respectively, compared to the total number of verified patients 
from both registries (Figure 1). This should be interpreted as 
an estimation of the registry completeness of true RA patients 
treated in hospital settings, as the two registries do not hold 
data of RA cases treated only in primary care.
By using the chi-square test and OLS regression with 
age in years as continuous variable and data source as 
dichotomous variable,  we tested whether a difference in 
the distribution of gender or age existed between the three 
groups of patients registered in DANBIO only, DNPR only, 
and overlapping based on data before record review.
Ethics
According to the rules at the time, the Danish Data Protection 
Agency was notified of the project’s use of data.
Results
Results from the data retrieval and review of patient records 
are shown in Figure 1. In 2011, a total of 664 incident patients 
with a diagnosis of RA were identified in DANBIO, and 2,088 
incident patients were identified in the DNPR. After merging 
data from the two data sources, and restricting patients from 
DNPR to include only those treated at hospital departments 
of rheumatology and those with two or more outpatient visits 
with RA as diagnosis, the number of patients in DANBIO 
only was 210, overlapping patients (both in DANBIO and in 
DNPR) was 423, and patients in DNPR only was 1,045. No 
differences were found in the distribution of gender or age 
between the three groups of patients (data not shown). The 
rheumatologists conducted reviews of the patient records in 
77%, 97%, and 92% of patients in the three groups (DAN-
BIO only, overlapping patients, and DNPR only; Figure 1).
The PPV of the RA diagnosis (as defined in Figure 1) 
was 92% for the DANBIO population and 79% for the 
DNPR population. With the inclusion of the updated DAN-
BIO dataset, the PPV of the RA diagnosis in DANBIO was 
96% (581 patients with verified RA from DNPR only were 
also identified in DANBIO with this update; Figure 1). The 
 registry completeness of relevant RA cases for DANBIO was 
43% based on the initial data, and 91% based on the updated 
data. For DNPR, it was 90% (Figure 1).
Table 1 shows the diagnoses in patients who, by review, 
were found to have a non-RA diagnosis. Osteoarthritis, 
Table 1 Distribution of diagnoses from patient records of non‑ra patients in the nationwide Clinical register for Patients with 
rheumatoid arthritis (DanBiO) and the Danish national Patient registry (DnPr), (n)
Diagnosis DANBIO only Both in DANBIO and DNPR DNPR only
arthralgia 2 5 36
Crystal arthropathy 0 0 16
Psoriatic arthritis 0 1 34
Osteoarthritis/spondyloarthritis 1 3 39
spondyloarthropathy 0 0 11
Juvenile arthritis 0 0 7
Polymyalgia 1 0 16
reactive arthritis 0 0 13
Oligo/polyarthritis 5 1 20
soft tissue rheumatism 0 0 5
Connective tissue diseases 1 0 10
Palindromic arthritis 0 0 7
Other 3 0 23
Missing 14 1 25
Total 27 11 262
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psoriatic arthritis, and arthralgia were the most frequent 
non-RA diagnoses.
Discussion
This study showed that 96% of RA patients registered in 
DANBIO and 79% of those in the DNPR were valid cases 
in the calendar year 2011. The completeness of relevant RA 
cases in each registry was estimated to be ~90% when a lag 
time between the period of interest and time of retrieving 
data was added.
The high validity of the diagnosis in DANBIO and the 
high percentage of false positive (one in five cases) in DNPR, 
even after applying rather strict filters, are important for 
future epidemiologic research projects in Danish RA patients. 
DANBIO is a clinical tool that gives an overview of patients’ 
disease course and is used by all rheumatologists providing 
routine care. The rheumatologists are also responsible for 
recoding data, if diagnoses are revised, and this contributes 
to the very high proportion of valid cases in DANBIO.
The discrepancy in numbers of incident RA cases between 
DANBIO and DNPR in the 2011 dataset was partly explained 
by a high false-positive rate of RA diagnoses in DNPR. More-
over, there was a delay in the registration of RA diagnoses 
in DANBIO as compared to the DNPR, probably because 
it often takes the clinician several months to establish the 
correct diagnosis, and the patient is only registered with the 
specific diagnosis RA in DANBIO thereafter. In contrast, the 
DNPR is an administrative registry, and the RA diagnosis 
is sometimes registered before it has been clinically con-
firmed – that is, at the time of referral. Some discrepancies 
between dates of diagnosis were found. In DANBIO, the 
month and year of diagnosis is entered by rheumatologists 
as a core variable. In the DNPR, the diagnosis is registered 
on the date of first in-or out-patient contact; therefore, the 
date of first contact may provide a poor indicator of the true 
diagnosis date.
The PPV of the RA diagnosis in DNPR was 79% when 
a previously developed filter was used for retrieving DNPR 
cases.6 For comparison, a recent study estimated the PPV of 
the Systemic Lupus Erythematosus diagnosis in DNPR to be 
~70%.15 Other recent validation studies of DNPR reported 
that the PPV was 80%–82% for acute coronary syndrome,16 
81% for epilepsy,17 and 92% for chronic obstructive pulmo-
nary disease 92%,18 based on specialists’ review of patient 
records. The Swedish National Patient Register reported a 
PPV of the RA diagnosis of 91%, using an algorithm that 
also included prescription of disease modifying drugs from 
the Swedish Prescribed Drug Register.19 A Canadian study 
found a PPV for RA of 51–83% in administrative data from 
both primary and secondary healthcare setups.20
We evaluated the RA diagnosis through review of a large 
number of patient records from nationwide data sources. 
It is, however, a limitation that milder cases of RA treated 
in the primary care sector by general practitioners are not 
included in the registries, but a strength that the practicing 
rheumatologists use and increasingly report into DANBIO.7 
In DANBIO’s annual quality report, the number of newly 
registered patients in DANBIO (rather than newly diagnosed) 
has been compared to the DNPR with no validation of the 
RA diagnosis. The proportions of RA patients in DNPR 
registered in DANBIO were calculated to be 79%, 83%, and 
85%, respectively, for the period 2011–2013,7 which indicates 
that registration practice, in general, has improved. This is 
in accordance with an increasing number of RA patients 
registered in DANBIO (>26,000 registered patients by spring 
20157), as a result of an increased focus on correct registra-
tions in both DANBIO and DNPR. The prevalence of RA in 
Denmark has previously been estimated to be 35,000 based 
on self-report surveys,21 which supports that a minor part of 
patients with RA are not followed in hospitals.22 It should, 
however, be noted that data on incident RA cases from DAN-
BIO before 2006 will probably have lower completeness of 
cases than reported in this study, because DANBIO registra-
tion of newly referred RA patients and RA patients receiving 
non-biological treatment first became mandatory in 2006.
It is an important finding for future epidemiologic 
research projects in Danish RA patients that the DANBIO 
registry provided a high proportion of valid diagnosis, 
although with a delay in registration of incident cases.
Conclusion
Based on a review of 1,532 incident cases, our study of two 
nationwide registries showed a high PPV of the RA diagnosis 
in DANBIO (96%) and a moderate PPV in DNPR (79%). 
The registry completeness of patients treated in hospital care 
was estimated to be ~90% in both registries.
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